Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Insider Arturo Md Molina Sells 26,000 Shares

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) insider Arturo Md Molina sold 26,000 shares of Protagonist Therapeutics stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $44.70, for a total value of $1,162,200.00. Following the sale, the insider now directly owns 46,444 shares of the company’s stock, valued at approximately $2,076,046.80. This trade represents a 35.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Arturo Md Molina also recently made the following trade(s):

• On Friday, November 15th, Arturo Md Molina sold 1,906 shares of Protagonist Therapeutics stock. The stock was sold at an average price of $40.98, for a total value of $78,107.88.

Protagonist Therapeutics Stock Performance

NASDAQ PTGX traded up $0.12 on Wednesday, reaching $44.95. The company’s stock had a trading volume of 569,522 shares, compared to its average volume of 750,584. Protagonist Therapeutics, Inc. has a twelve month low of $17.13 and a twelve month high of $48.89. The stock has a market cap of $2.68 billion, a PE ratio of 16.85 and a beta of 2.17. The firm’s 50 day moving average is $45.24 and its two-hundred day moving average is $39.58.

Wall Street Analyst Weigh In

PTGX has been the subject of a number of recent analyst reports. StockNews.com upgraded shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Protagonist Therapeutics in a research note on Tuesday, November 19th. JMP Securities decreased their target price on shares of Protagonist Therapeutics from $45.00 to $43.00 and set a “market outperform” rating on the stock in a research report on Wednesday, August 7th. TD Cowen upgraded shares of Protagonist Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 25th. Finally, Truist Financial began coverage on shares of Protagonist Therapeutics in a report on Monday, September 9th. They issued a “buy” rating and a $60.00 price target for the company. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $53.57.

Hedge Funds Weigh In On Protagonist Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Franklin Resources Inc. increased its holdings in Protagonist Therapeutics by 127.2% in the third quarter. Franklin Resources Inc. now owns 81,591 shares of the company’s stock worth $3,782,000 after buying an additional 45,674 shares during the last quarter. Teachers Retirement System of The State of Kentucky bought a new stake in shares of Protagonist Therapeutics in the third quarter valued at approximately $909,000. Geode Capital Management LLC boosted its position in shares of Protagonist Therapeutics by 0.3% in the third quarter. Geode Capital Management LLC now owns 1,374,697 shares of the company’s stock valued at $61,873,000 after acquiring an additional 3,528 shares during the period. Barclays PLC boosted its position in shares of Protagonist Therapeutics by 223.6% in the third quarter. Barclays PLC now owns 126,995 shares of the company’s stock valued at $5,714,000 after acquiring an additional 87,755 shares during the period. Finally, XTX Topco Ltd bought a new stake in shares of Protagonist Therapeutics in the third quarter valued at approximately $666,000. Institutional investors and hedge funds own 98.63% of the company’s stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.